Investigational Drug Details
| Drug ID: | D297 |
| Drug Name: | Raltegravir |
| Synonyms: | Raltegravir |
| Type: | Chemical drug |
| DrugBank ID: | DB06817 |
| DrugBank Description: | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. |
| PubChem ID: | 54671008 |
| CasNo: | 518048-05-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(NC(=O)c1nnc(o1)C)(C)(C)c1nc(C(=O)NCc2ccc(cc2)F)c(c(=O)n1C)O |
| Structure: |
|
| InChiKey: | CZFFBEXEKNGXKS-UHFFFAOYSA-N |
| Molecular Weight: | 444.423 |
| DrugBank Targets: | Integrase inhibitor |
| DrugBank MoA: | Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome. Raltegravir is primarily metabolized by glucuronidation. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | For the treatment of HIV-1 infection in conjunction with other antiretrovirals. |
| Targets: | -- |
| Therapeutic Category: | Anti-HIV drug |
| Clinical Trial Progress: | Clinical trial on-going (NCT02210715) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0625 | NCT02210715 | Phase 4 | Recruiting | No Results Available | 05/08/2014 | 16 December 2017 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A02034 | 34524919 | AIDS Patient Care STDS | Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. | Details |
| A04824 | 33493297 | Clin Infect Dis | Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir. | Details |
| A10729 | 31219362 | Infect Dis (Lond) | Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. | Details |
| A15445 | 28903510 | Clin Infect Dis | Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. | Details |
| A52245 | 29746485 | PLoS One | Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy. | Details |